<table><thead><tr><td>Particulars</td><td>2024-25</td><td>2023-24</td><td>2022-23</td></tr></thead><tbody><tr><td>Existing Capacity- Kits)</td><td>1272000</td><td>1272000</td><td>1272000</td></tr><tr><td>Capacity Utilization</td><td>45%</td><td>31%</td><td>28%</td></tr></tbody></table>

## Quality Control

We have implemented current good manufacturing practices across our manufacturing facilities, encompassing different areas of business processes from supply chain to product delivery. We are committed to complying with regulatory requirements and standards applicable to our operations. We believe that the maintenance of high standards of quality and manufacturing processes, is a key differentiator in our business and critical to our brand and continued growth. This enables us to maintain consistent quality, efficiency and product safety. We have a comprehensive approach towards quality and have adopted streamlined manufacturing procedures across all our facilities aimed towards achieving standardized quality and ensuring compliance with regulatory requirements.

Our focus on quality standards is supported by our quality control and quality assurance team member. Our facilities are ISO and GMP-certified, which encompasses best industry practices including for adequate premises and space, suitable equipment and services, appropriate materials, approved procedures and instructions, and equipped laboratories. Further, we have been granted below certification for quality assurance -

1. ISO 13485:2016 for design, manufacture and distribution of in-vitro diagnostic reagents and instruments.

2. ISO 9001:2015 for Quality Management System.

## Research & Development

Our in-house R&D capabilities are critical to our operations and continued growth. Accordingly, we are increasingly engaged in R&D programs to develop innovative product and manufacturing methods. As of March 31, 2025, we employed 23 personnel in our R&D department. Our R&D undertakes development team of formulations, analytical methods, packaging and stability studies, and have been instrumental to our product development. The team is also involved in specification development for products. In addition, through packaging development, we select appropriate packing components to ensure the safety, stability and efficacy of packed products.

## Export Obligation

As on date of Draft Red Herring Prospectus, our Company does not have any export obligations.

## Collaborations

The Company has entered into Technology Transfer Agreements (TTAs) with global diagnostic companies for strengthening its product portfolio. The Company has received technology transfer for Clinical Chemistry Analysers including Selectra PRO M, Micro Lab 300 and Selectra PRO XL. Selectra PRO M is already being manufactured at the Company's Lucknow plant with royalty payable, while Micro Lab 300 is under development and is expected to be available for commercial sale by FY27. The Company has also entered TTAs for Haematology Reagents and the M-20 CBC Cell Counter. Haematology Reagents are already being manufactured at the Lucknow plant, where royalty is payable on RFID tags. The M-20 CBC Cell Counter is under development and is expected to be available for commercial sale by Q4 FY26.

## Raw Materials and Suppliers

The key raw materials and supplies that we use for our varying manufacturing operations are Power Supply PT535, Data cable tree, Panel PC, Measuring Unit, temperature control board for instrument manufacturing and Bulk Reagent, Antigen, Antibody Enzymes Subtracts for reagent manufacturing. We are dependent on various suppliers both in India and overseas for our raw materials supplies. We monitor the availability and pricing of raw materials on a regular basis and leverage our purchasing power to ensure that we have access to raw materials in a cost-efficient manner. We do not have any long-term contracts with our all suppliers and prices are typically negotiated for each purchase order. We also conduct quality checks on raw materials supplied by our suppliers periodically to maintain quality standards in accordance with applicable regulatory requirements.

Below table represents the data for the purchases made in the last 3 years from both the international and domestic market.

(in Lakhs)

<table><thead><tr><td>Particulars</td><td>March 31, 2025</td><td>March 31, 2024</td><td>March 31, 2023</td></tr></thead><tbody><tr><td>Domestic Market</td><td>5689.59</td><td>3941.83</td><td>2553.02</td></tr><tr><td>International Market</td><td>8680.93</td><td>11707.65</td><td>7169.71</td></tr></tbody></table>